Bizarre Patents
Wearable Device For Feeding and Observing Birds and Other Flying Animals
A device for feeding and observing flying animals comprising a hat, a support mounted on the hat and extending outward from the hat, and a feeder mounted on the support.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120045457 | NONTYPABLE HAEMOPHILUS INFLUENZAE ANTIGENS The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furtherm... | 02/23/2012 |
| 20120020979 | METHODS FOR TREATING IgE-MEDIATED DISORDER This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents fr... | 01/26/2012 |
| 20120003277 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam... | 01/05/2012 |
| 20110300179 | Novel Compositions and Uses Thereof The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid m... | 12/08/2011 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110223174 | Nontypeable Haemophilus Influenzae Virulence Factors The invention relates to a mutation within the sap operon of an avirulent clone of a nontypeable strain of Haemophilus influenzae (NTHi). The invention also relates to the NTHi sap operon genes and the polypeptides encoded by these polynucleotide sequences. The i... | 09/15/2011 |
| 20110206765 | Non-Typeable Haemophilus Influenzae Vaccines and Their Uses Provided are non-typeable Haemophilus influenzae vaccines useful for the treatment of chronic obstructive pulmonary disease and asthma in a patient. In certain aspects, the vaccine is a monobacterial vaccine. Bacterial strains for use in the vaccines of the prese... | 08/25/2011 |
| 20110200616 | Immunizing Compositions and Methods of Use The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also... | 08/18/2011 |
| 20110159030 | MUCOSAL COMBINATION VACCINES FOR BACTERIAL MENINGITIS A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune response against Neisseria meningitidis; and (c) an antigen ... | 06/30/2011 |
| 20110142881 | TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular ... | 06/16/2011 |
| 20110104207 | GYRASE INHIBITORS AND USES THEREOF The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention al... | 05/05/2011 |
| 20110081357 | Chimeric Vaccine for Haemophilus Influenzae-Induced Disease The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and... | 04/07/2011 |
| 20110014237 | Vaccine for Protection Against Haemophilus Parasuis Serotype 4 in Piglets The present invention pertains to the use of Haemophilus parasuis serotype 5 bacteria in the manufacture of a vaccine for administration to a pregnant sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt after she has farrowed,... | 01/20/2011 |
| 20100310569 | Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to ... | 12/09/2010 |
| 20100285064 | ADJUVANT COMPOSITION FOR VACCINE The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.... | 11/11/2010 |
| 20100285070 | POLYNUCLEOTIDES OF HAEMOPHILUS PARASUIS AND ITS USE The present invention relates to Haemophilus parasuis polynucleotides produced by recombinant technology. It also relates to polypeptides that are expressed by said polynucleotides and also to a vaccine against H. parasuis that comprises said polypeptides.... | 11/11/2010 |
| 20100272758 | Viable non-toxic gram-negative bacteria The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention... | 10/28/2010 |
| 20100255035 | Modified live (JMSO strain) Haemophilus parasuis vaccine The present invention is a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs as a live vaccine. The present invention is also a method of preparing the cel... | 10/07/2010 |
| 20100233201 | VACCINE COMPOSITION The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of H. influenzae B (PRP). Immunogenic compositions and methods ... | 09/16/2010 |
| 20100150967 | TREATMENT OR PROPHYLAXIS OF ASTHMA There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae (NTHi) vaccine. The vaccine is typically an oral whole killed NTHi... | 06/17/2010 |
| 20100112078 | POLYMER PARTICLES BASED VACCINE The present invention provides a vaccine composition comprising an effective amount of antigen or a nucleic acid encoding antigen, encapsulated in polymeric particles, wherein said polymeric particles comprises nanoparticles, microparticles or combinations thereof, wher... | 05/06/2010 |
| 20100074922 | Pneumococcal polysaccharide conjugate vaccine The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae | 03/25/2010 |
| 20100028448 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprisin... | 02/04/2010 |
| 20090297559 | USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pu... | 12/03/2009 |
| 20090263421 | CELLULAR VACCINE The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nuc... | 10/22/2009 |
| 20090181054 | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conju... | 07/16/2009 |
| 20090175912 | Haemophilus Influenza Outer Membrane Protein and Use Thereof in Vaccination This invention relates to recombinant bacterial outer membrane proteins comprising one or more LB1(f) peptides from surface-exposed loop 3 of MOMP P5 of non-typeable H. influenzae. Polynucleotides encoding these recombinant proteins are also covered. The inventio... | 07/09/2009 |
| 20090155330 | Vaccine Delivery via Microneedle Arrays A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another ... | 06/18/2009 |
| 20090110699 | Antigen-Adjuvant Compositions and Methods Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine com... | 04/30/2009 |
| 20090092629 | VACCINE FOR NONTYPEABLE HAEMOPHILUS INFLUENZAE INFECTION This invention provides a method for identifying strains of nontypeable Haemophilus influenzae that can be used as immunogenic compositions having specificity against a plurality of Haemophilus influenzae strains. The invention also provides compositions c... | 04/09/2009 |
| 20090017074 | CULTURE MEDIUM FOR HAEMOPHILUS INFLUENZAE TYPE B The invention relates to a culture medium for Haemophilus influenzae type b, characterized in that the source of protein nitrogen is of non-animal origin and comprises at least one plant peptone and in that the heme source consists of protoporphyrin IX. This medi... | 01/15/2009 |
| 20090010964 | Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered w... | 01/08/2009 |
| 20080311156 | VACCINES The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by ... | 12/18/2008 |
| 20080279880 | PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) ... | 11/13/2008 |
| 20080112925 | QS-21 AND IL-12 AS AN ADJUVANT COMBINATION Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. The... | 05/15/2008 |
| 20080044440 | Vaccine Formulated For Administration To Mucosa Of The Lungs There is disclosed vaccines formulated for administration to the mucosa of the lungs of a mammal, and the use thereof in methods for prophylaxis or treatment of an infection by at least one pathogenic microorganism. The vaccines comprise a cellular fraction of the micro... | 02/21/2008 |
